What We're Reading: Page 2
Industry reads hand-picked by our editors
Jan 26, 2026
-
The Wall Street Journal
Merck No Longer in Talks to Buy Revolution Medicines
-
Bloomberg
Llamas Are Big Pharma’s Secret Weapon to Find New Drugs
-
Fierce Biotech
‘Things are looking up’: British biotechs consider going public after yearslong IPO drought
-
NPR
Here’s how ‘shared decision making’ for childhood vaccines could limit access
Jan 23, 2026
Jan 22, 2026
Jan 21, 2026
-
The Economist
Treatment of a teenager with an ultra-rare condition is a medical milestone
-
Fierce Biotech
Nkarta’s CEO wore head-to-toe pink at JPM. Here’s why it matters more than ever
-
ApexOnco
Genmab’s Rybrevant challenge is rendered moot
-
CNBC
Zydus Life may acquire US-firm Ardelyx, may raise funds via QIP to part-fund deal
Jan 20, 2026
-
Nature
‘Shattered’: US scientists speak out about how Trump policies disrupted their careers
-
The Washington Post
Why the same cold virus makes some people more miserable than others
-
The Wall Street Journal
Novo Nordisk Aims to Set Ozempic Apart From Other GLP-1s in New Ad Campaign
-
Reuters
Abivax CEO dismisses ‘noise’ around rumored Eli Lilly bid
Jan 16, 2026
Jan 15, 2026
-
Reuters
US FDA delays two drug reviews in new voucher program after safety, efficacy concerns
-
The New York Times
China’s ‘Dr. Frankenstein’ Thinks Time Is on His Side
-
The Atlantic
The Best Flu Drug Americans Aren’t Taking
-
The Financial Times
Vaccines are no longer immune to pharma’s market swings
Previous
